Blog

Dec 10, 2024, 13:53

97P Neoadjuvant D+GemCis vs gemcis alone for localized biliary tract cancer

Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute and Post DM senior resident at AIIMS, New Delhi, shared on X:

”97P Neoadjuvant durvalumab plus gemcitabine and cisplatin (D+GemCis) versus gemcis alone for localized biliary tract cancer (BTC): Results of a randomized, multicenter, open-label, phase II trial (DEBATE) – Annals of Oncology”

Authors: C. Yoo, J.O. Park, K-P. Kim, J. Hyung, B-Y. Ryoo, J.Y. Hong, S.H. Shin, T.J. Song, D. Oh, W. lee, B.J. Kwak, J.H. Lee, D.W. Hwang

Akhil Santhosh Annals of Oncology B-Y. Ryoo B.J. Kwak C. Yoo cancer D. Oh D.W. Hwang J. Hyung J.H. Lee J.O. Park J.Y. Hong K-P. Kim OncoDaily Oncology S.H. Shin T.J. Song W. lee

"The Doctor Who Always Has Candies in His Pocket": A Conversation with Professor Guangchao Zhang, Pioneer of Pediatric Surgical Oncology in China

Wanda Sykes and Breast Cancer: How She Went Against, How She Survived, and More

Highlights from Global Cancer Movement: Challenging the Status Quo in Colorectal Cancer - Day 2

Highlights from Global Cancer Movement: Challenging the Status Quo in Colorectal Cancer - Day 1

100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2024

Special Coverage